226 related articles for article (PubMed ID: 19561292)
1. Role of hematopoietic stem cell transplant in the management of follicular lymphoma.
Foster M; Gabriel DA; Shea T
Oncologist; 2009 Jul; 14(7):726-38. PubMed ID: 19561292
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation in follicular lymphoma.
Khouri IF
Best Pract Res Clin Haematol; 2011 Jun; 24(2):271-7. PubMed ID: 21658623
[TBL] [Abstract][Full Text] [Related]
3. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
4. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
6. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.
Piñana JL; Martino R; Gayoso J; Sureda A; de la Serna J; Díez-Martín JL; Vazquez L; Arranz R; Tomás JF; Sampol A; Solano C; Delgado J; Sierra J; Caballero D;
Haematologica; 2010 Jul; 95(7):1176-82. PubMed ID: 20107156
[TBL] [Abstract][Full Text] [Related]
7. Transplantation strategies for patients with follicular lymphoma.
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Curr Opin Hematol; 2005 Jul; 12(4):266-72. PubMed ID: 15928482
[TBL] [Abstract][Full Text] [Related]
8. The role of hematopoietic stem cell transplant in follicular lymphoma.
Faber EA; Vose JM
J Natl Compr Canc Netw; 2010 Mar; 8(3):337-44; quiz 345. PubMed ID: 20202463
[TBL] [Abstract][Full Text] [Related]
9. Improving outcomes in transplantation.
Brugger W
Semin Oncol; 2002 Apr; 29(2 Suppl 6):23-6. PubMed ID: 12040531
[TBL] [Abstract][Full Text] [Related]
10. The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma.
Laport GG
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):59-65. PubMed ID: 16399587
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
12. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
13. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
Tam CS; Bassett R; Ledesma C; Korbling M; Alousi A; Hosing C; Kebraei P; Harrell R; Rondon G; Giralt SA; Anderlini P; Popat U; Pro B; Samuels B; Hagemeister F; Medeiros LJ; Champlin RE; Khouri IF
Blood; 2009 Apr; 113(18):4144-52. PubMed ID: 19168784
[TBL] [Abstract][Full Text] [Related]
14. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
15. Autologous transplant of follicular lymphoma in the era of rituximab.
Witzens-Harig M; Dreger P
Leuk Lymphoma; 2010 Jun; 51(6):967-74. PubMed ID: 20443675
[TBL] [Abstract][Full Text] [Related]
16. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Khouri IF; McLaughlin P; Saliba RM; Hosing C; Korbling M; Lee MS; Medeiros LJ; Fayad L; Samaniego F; Alousi A; Anderlini P; Couriel D; de Lima M; Giralt S; Neelapu SS; Ueno NT; Samuels BI; Hagemeister F; Kwak LW; Champlin RE
Blood; 2008 Jun; 111(12):5530-6. PubMed ID: 18411419
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C; Gopal AK; Storer BE; Cassaday RD; Press OW; Till BG; Pagel JM; Palanca-Wessels MC; Philip M; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Chauncey T; Maloney DG; Libby EN
Leuk Lymphoma; 2015 Jan; 56(1):92-6. PubMed ID: 24707941
[TBL] [Abstract][Full Text] [Related]
18. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Lazzarino M; Arcaini L; Bernasconi P; Alessandrino EP; Gargantini L; Cairoli R; Orlandi E; Astori C; Brusamolino E; Pagnucco G; Colombo AA; Calatroni S; Iacona I; Regazzi MB; Morra E
Br J Haematol; 2002 Jan; 116(1):229-35. PubMed ID: 11841421
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Bertz H; Illerhaus G; Veelken H; Finke J
Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
